Med Life SA · BVB:M
Med Life SA — 9M 2020 Earnings Presentation
18 slides from Med Life SA's earnings presentation, Dec 3, 2020
Slide 1: 9m 2020 Financial Results
9m 2020 Financial Results Investors and Analysts presentation 2-3 December 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Key messages 9m 2020 Highlights 9m 2020 AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights 9m 2020
Highlights 9m 2020 • Key messages 9m 2020 1 4/
Slide 5: Key messages 9m 2020
Key messages 9m 2020 MedLife Group focused on helping patients and state institutions during the pandemic and has shaped its business model to address the new business and economic environment, while still focusing on providing new medical services requested by patients during this period; The top p
Slide 6: Key messages 9m 2020
Key messages 9m 2020 Quick adaptability to new services, repositioning on labs & the mix of medical activities in the area of hospitals, clinics, corporate, pharma and dentistry, helped to meet patients` demand and offer a solid perspective for the Group for the period post-COVID; ➢ Clinics ➢ Labora
Slide 7: Key messages 9m 2020
Key messages 9m 2020 The development of 4 COVID-19 laboratories, in record time, was one of the important achievements of the group in this period. Through these, the company was able to keep MedLife employees safe, to periodically test medical and auxiliary staff and patients and keep the units fun
Slide 8: Key messages 9m 2020: Operating profit and EBITDA
Key messages 9m 2020 Operating profit and EBITDA The Group tailored its services to meet new demands and optimized the business dynamics; Managed to increase operating profit and EBITDA as a result of cost-cutting measures aimed at generating sustainable performance improvements in all business line
Slide 9: Outlook for end of year and 2021
Key messages 9m 2020 Outlook for end of year and 2021 The strategy is to be prepared for post-COVID period when we expect an increase in traffic in all medical units, and a closer relation between general practitioners, small clinics and pharmacies; We will continue development and expansion plans,
Slide 10: Outlook for end of year and 2021
Key messages 9m 2020 Outlook for end of year and 2021 On M&A side, interest in several opportunities in the market, including pharma segment, expected to have an important contribution to economic recovery and maintaining the health of the population in the years to come. In this respect, the Group
Slide 11: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 11 /
Slide 12: Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) 9m 2020 Pro-forma vs. 9m 2019 IFRS ❑ Sales increased by 5.1%, to 747.2m RON ❑ OPEX remained flat, at 672.6m RON ❑ EBIT increased by 78% to 78m RON, 10.4% margin (6.2%) ❑ EBITDA increased by 38% to 156.9m RON, 21% margin (16%) ❑ EBITDA before IFRS 16 in
Slide 13: Profit and Loss (2/3)
Consolidated Statement of Profit and Loss (2/3) Operational KPIs Sales for 9m 2020 increased by 8.4% vs 9m 2019 (on IFRS), and by 5.1% vs 9m 2019 (Pro-forma) as an effect of: ➢ Acquisitions made subsequent to 9m2019 ➢ strong operating performance in January and February ➢ drop in sales starting with
Slide 14: Profit and Loss (3/3) OPEX Evolution
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution 14 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 15: Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) 15 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 16: Financial Position (2/2) Debt position
Consolidated Statement of Financial Position (2/2) Debt position 16 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 17: Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by good operating performance, reinforced by controls and saving measures: 1. 61% increase in net cash from operating activities; 2. 80% increase in cash used in investing activities; 3. Increase in cash with 22.9m RON from f
Slide 18: Q&A Session Thank you!
Q&A Session Thank you! 3 18 /